Completed PHASE2 INTERVENTIONAL 11-arm NCT01786512

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF)

A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With Heart Failure and Left Ventricular Systolic Dysfunction

Sponsor: Cytokinetics

Conditions Chronic Heart Failure Echocardiogram History of Chronic Heart Failure Left Ventricular Ejection Fraction Left Ventricular Systolic Dysfunction Modified Release Oral Formulation Pharmacokinetics

Interventions Omecamtiv Mecarbil Matrix F1 Formulation Omecamtiv Mecarbil Matrix F2 Formulation Omecamtiv Mecarbil Swellable Core Technology F2 Placebo

Updated 10 times since 2017 Last updated: Jul 25, 2021 Started: Feb 26, 2013 Primary completion: Jul 22, 2015 Completion: Aug 19, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Heart Failure and Echocardiogram and is currently completed. Cytokinetics leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2021 — Sep 2021 [monthly]

Completed PHASE2

▶ Show 5 earlier versions

Jan 2021 — Jun 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Sep 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cytokinetics

Data source: Cytokinetics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amersfoort, Netherlands , Antwerp, Belgium , Atlanta, United States , Atlantis, United States , Auburn, United States , Aventura, United States , Bad Krozingen, Germany , Bad Nauheim, Germany , Baltimore, United States , Berlin, Germany and 85 more locations